CompletedNot Applicable

Trial of MRSA Polymerase Chain Reaction for Pneumonia

United States45 participantsStarted 2016-01

Plain-language summary

The purpose of this study is to conduct a randomized clinical trial to compare an antibiotic strategy based on a novel diagnostic test, polymerase chain reaction (PCR) to usual care, in critically ill adults with pneumonia suspected to be caused by methicillin resistant staphylococcus aureus (MRSA). The investigators hypothesize that when automated PCR is used to guide antibiotic therapy, antibiotic exposure will be reduced in critically ill subjects with pneumonia.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged 18 years and older with known or suspected pneumonia who are endotracheally intubated and mechanically ventilated
✓. Can receive bronchoalveolar lavage (BAL) while intubated
✓. Have received 24 hours or less of MRSA therapy (the antibiotics vancomycin or linezolid) prior to study enrollment

Exclusion criteria

✕. More than 24 hours of MRSA therapy therapy (the antibiotics vancomycin or linezolid),
✕. Subjects with extra pulmonary infection requiring treatment with vancomycin or linezolid
✕. Neutropenic fever
✕. Chronic airway infection
✕. Patient/surrogate refusal
✕. Subjects in whom BAL is deemed unsafe by the treating physician
✕. Treating physician refusal to discontinue antibiotics to treat MRSA if PCR negative
✕. Prisoners

What they're measuring

Days of anti-MRSA antibiotic therapy

Timeframe: 14 days

Trial details

NCT IDNCT02660554

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-02-28

View on ClinicalTrials.gov More Pneumonia trials